Viewing nowCombinationJanualin Duo Tablets 50/850 mg
Sitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Il Yang Pharmaceutical Co., Ltd.

MFDS item code 202200304 · Approved 2022.01.19 · Insurance code 641706180
Improvement of glycemic control in patients with type 2 diabetes mellitus
This drug is used to help control blood sugar in patients with type 2 diabetes. It may be administered when monotherapy is insufficient for adequate glycemic control in individuals who have not previously received diabetes medication treatment. It is also used when blood sugar control is difficult with either metformin or sitagliptin alone, or when replacing the combination therapy of these two medications. This drug can be added to enhance therapy when blood sugar is inadequately controlled by the combination of metformin and sulfonylurea, or metformin and thiazolidinedione. If sufficient glycemic control is not achieved with insulin and metformin, this drug may be used in combination. In various situations, it effectively improves blood sugar control in patients with type 2 diabetes.
For antidiabetic therapy, determine the dose of this medicine based on the patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This medicine is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. The initial dose of this medicine should be determined according to the patient's current treatment regimen. 1. Patients not currently receiving metformin: For patients with no previous history of antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom sitagliptin monotherapy does not provide adequate glycemic control, the initial dose is 1 tablet of this medicine 50/500 mg twice daily. The dose may be increased to 1 tablet of this medicine 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this medicine (see Precautions for Use, 2. Patients Who Must Not Take This Medicine). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg) together with the patient's current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this medicine may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this medicine is sitagliptin 50 mg twice daily (total daily dose 100 mg); the initial dose of metformin should be determined based on the patient's blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, increase the dose gradually. When administered with a sulfonylurea or insulin, consider reducing the dose of the sulfonylurea or insulin to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral antihyperglycemic agents to this medicine. Any change in treatment for type 2 diabetes may alter glycemic control; use caution and ensure appropriate monitoring. Patients with renal impairment This medicine may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustment. Treatment with this medicine should not be initiated because the starting dose of metformin is 500 mg or 850 mg once daily. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be carefully monitored every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, discontinue this medicine immediately. Patients with hepatic impairment This medicine must not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Take This Medicine).
This drug contains sitagliptin and metformin, both of which are used in the treatment of diabetes. Firstly, sitagliptin can rarely cause serious allergic reactions, so if symptoms such as skin rash, hives, or difficulty breathing occur, the patient should stop taking the medication immediately and seek medical attention. Additionally, there is a risk of acute pancreatitis, which can cause inflammation of the pancreas, so if abdominal pain, vomiting, or severe abdominal pain occurs, a medical facility should be visited promptly. Metformin can rarely cause a serious metabolic abnormality called lactic acidosis, which is a dangerous condition that occurs when lactic acid accumulates excessively in the body. This condition is particularly likely to occur in patients with poor kidney function, liver dysfunction, severe infections, or dehydration. This drug should not be administered to patients with moderate to severe decreased kidney function, acute heart failure, acute myocardial infarction, sepsis, or other acute diseases. Furthermore, the use of this drug should be temporarily discontinued before and after undergoing examinations that use radiologic contrast agents due to the risk of worsening kidney function and lactic acidosis. It is also not recommended for pregnant women or nursing mothers. Patients should be vigilant for hypoglycemic symptoms while taking this medication, especially if it is taken in conjunction with insulin or sulfonylurea, as the risk of hypoglycemia is heightened. Moreover, this drug can occasionally cause gastrointestinal disturbances (diarrhea, nausea, vomiting, abdominal pain), headaches, and upper respiratory infections. If symptoms are severe, patients should consult their doctor. Regular kidney function and blood tests should be conducted before and during treatment, and vitamin B12 levels should also be periodically checked. Alcohol can increase the risk of lactic acidosis while taking this medication, so excessive drinking should be avoided. If eating becomes difficult due to surgery or significant illness, the use of this drug should be temporarily suspended and resumed after recovery. Finally, if severe joint pain or blisters on the skin occur while taking this medication, the patient should immediately inform their doctor. This drug requires careful monitoring and regular testing based on the patient's condition, and medical personnel should be consulted immediately if abnormal symptoms occur.
Anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, lactic acidosis, hypoglycemia, diarrhea, upper respiratory infection, headache, nausea, vomiting, abdominal pain, nasopharyngitis, constipation, arthralgia accompanied by severe symptoms and disabilities, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, dermatitis, anorexia, weight loss, dyspnea, unstable angina, dizziness, acute kidney failure, decreased appetite, gastrointestinal disturbance, itching
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in an airtight container to prevent exposure to air or moisture. It is advisable to maintain a storage temperature between 1 degree and 30 degrees Celsius at room temperature. Proper storage will help maintain the drug's efficacy and safety.
Pink oval film-coated tablet
30 tablets/box [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Il Yang Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Daewon Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 505mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 858.5mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Samsung Pharmaceutical Co., Ltd.
CombinationSitagliptin Hydrochloride Hydrate 56.7mg · Metformin Hydrochloride with Colloidal Anhydrous Silica 1010mg
Tablet · Prescription medication · Combination
Eden Pharma Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.